216 related articles for article (PubMed ID: 21923736)
41. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?
Leibowitz G; Cerasi E
Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909
[TBL] [Abstract][Full Text] [Related]
42. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
[TBL] [Abstract][Full Text] [Related]
43. Role of sulfonylurea receptor type 1 subunits of ATP-sensitive potassium channels in myocardial ischemia/reperfusion injury.
Elrod JW; Harrell M; Flagg TP; Gundewar S; Magnuson MA; Nichols CG; Coetzee WA; Lefer DJ
Circulation; 2008 Mar; 117(11):1405-13. PubMed ID: 18316485
[TBL] [Abstract][Full Text] [Related]
44. The effect of gliquidone on KATP channels in pancreatic β-cells, cardiomyocytes, and vascular smooth muscle cells.
Liu SY; Tian HM; Liao DQ; Chen YF; Gou ZP; Xie XY; Li XJ
Diabetes Res Clin Pract; 2015 Aug; 109(2):334-9. PubMed ID: 26044612
[TBL] [Abstract][Full Text] [Related]
45. Isoflurane activates sarcolemmal adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells: a role for protein kinase A.
Tanaka K; Kawano T; Nakamura A; Nazari H; Kawahito S; Oshita S; Takahashi A; Nakaya Y
Anesthesiology; 2007 May; 106(5):984-91. PubMed ID: 17457130
[TBL] [Abstract][Full Text] [Related]
46. A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) channels.
Yamada M; Kurachi Y
J Mol Cell Cardiol; 2005 Jul; 39(1):1-6. PubMed ID: 15978900
[TBL] [Abstract][Full Text] [Related]
47. Imaging docking and fusion of insulin granules induced by antidiabetes agents: sulfonylurea and glinide drugs preferentially mediate the fusion of newcomer, but not previously docked, insulin granules.
Nagamatsu S; Ohara-Imaizumi M; Nakamichi Y; Kikuta T; Nishiwaki C
Diabetes; 2006 Oct; 55(10):2819-25. PubMed ID: 17003348
[TBL] [Abstract][Full Text] [Related]
48. [Molecular basis of oral hypoglycemic sulfonylurea action].
Owecki M; Horst-Sikorska W; Sowiński J
Pol Merkur Lekarski; 2003 Nov; 15(89):445-8. PubMed ID: 14969140
[TBL] [Abstract][Full Text] [Related]
49. The mechanisms underlying the unique pharmacodynamics of nateglinide.
Hu S; Boettcher BR; Dunning BE
Diabetologia; 2003 Mar; 46 Suppl 1():M37-43. PubMed ID: 12652357
[TBL] [Abstract][Full Text] [Related]
50. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
[TBL] [Abstract][Full Text] [Related]
51. Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components.
Ball AJ; McCluskey JT; Flatt PR; McClenaghan NH
Pharmacol Res; 2004 Jul; 50(1):41-6. PubMed ID: 15082027
[TBL] [Abstract][Full Text] [Related]
52. SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandil.
Shindo T; Yamada M; Isomoto S; Horio Y; Kurachi Y
Br J Pharmacol; 1998 Jul; 124(5):985-91. PubMed ID: 9692785
[TBL] [Abstract][Full Text] [Related]
53. [Drugs stimulating insulin release. Importance of their use for improving glycemia, safety and quality of life in diabetes mellitus type 2].
Sieradzki J
Przegl Lek; 2000; 57(1):5-8. PubMed ID: 10907360
[TBL] [Abstract][Full Text] [Related]
54. Uncoupling by (--)-epigallocatechin-3-gallate of ATP-sensitive potassium channels from phosphatidylinositol polyphosphates and ATP.
Jin JY; Park SH; Bae JH; Cho HC; Lim JG; Park WS; Han J; Lee JH; Song DK
Pharmacol Res; 2007 Sep; 56(3):237-47. PubMed ID: 17656102
[TBL] [Abstract][Full Text] [Related]
55. Sulfonylurea induced beta-cell apoptosis in cultured human islets.
Maedler K; Carr RD; Bosco D; Zuellig RA; Berney T; Donath MY
J Clin Endocrinol Metab; 2005 Jan; 90(1):501-6. PubMed ID: 15483097
[TBL] [Abstract][Full Text] [Related]
56. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
Hee Nam Y; Brensinger CM; Bilker WB; Flory JH; Leonard CE; Hennessy S
Clin Pharmacol Ther; 2022 Jan; 111(1):218-226. PubMed ID: 34312836
[TBL] [Abstract][Full Text] [Related]
57. Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
Tagmose TM; Schou SC; Mogensen JP; Nielsen FE; Arkhammar PO; Wahl P; Hansen BS; Worsaae A; Boonen HC; Antoine MH; Lebrun P; Hansen JB
J Med Chem; 2004 Jun; 47(12):3202-11. PubMed ID: 15163199
[TBL] [Abstract][Full Text] [Related]
58. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
Landgraf R
Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
[TBL] [Abstract][Full Text] [Related]
59. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium.
Quast U; Stephan D; Bieger S; Russ U
Diabetes; 2004 Dec; 53 Suppl 3():S156-64. PubMed ID: 15561904
[TBL] [Abstract][Full Text] [Related]
60. A key role for the subunit SUR2B in the preferential activation of vascular KATP channels by isoflurane.
Fujita H; Ogura T; Tamagawa M; Uemura H; Sato T; Ishida A; Imamaki M; Kimura F; Miyazaki M; Nakaya H
Br J Pharmacol; 2006 Nov; 149(5):573-80. PubMed ID: 17001304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
